LYMPHOMAS

In part C of the phase 2 SGN35-027 trial evaluating brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine in patients with classical Hodgkin lymphoma, fewer than half of patients developed primarily low-grade peripheral neuropathy, and no cases of febrile neutropenia were observed.

The use of polatuzumab vedotin in place of vincristine in R-mini-CHOP may lead to an increase in gastrointestinal adverse events in frail patients with diffuse large B-cell lymphoma.

At the second planned interim analysis of the phase 3 SWOG S1826, the primary progression-free survival end point crossed the protocol-specified statistical boundary.

During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the use of brentuximab vedotin in patients with Hodgkin lymphoma. This is the second of 2 articles based on this event.

Matthew Matasar, MD, discusses the development of mosunetuzumab and how it is a positive step forward in the field of follicular lymphoma treatment.

The fast track designation to IMPT-314 is for the treatment of multiple types of B-cell lymphoma in patients who previously received 2 or more lines of systemic therapy.

The FLASH study and compatibility study of SGX301 led to promising safety and efficacy responses for the treatment of cutaneous T-cell lymphoma. Now, the FDA has granted a type A meeting to discuss the design of a second trial of SGX301.

On the heels of a positive ODAC vote, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is now FDA-approved.

The FDA has requested positive results from a second clinical study of SGX301 in patients with early stage cutaneous T-cell lymphoma before filing a new drug application.

Mixed study results for ibrutinib have led the developer to voluntarily withdraw the agent from the United States market for the treatment of mantle cell and marginal zone lymphoma subgroups.

Tycel Phillips, MD, discusses the agents available for the second-line treatment of diffuse large B-cell lymphoma, and the utility of chimeric antigen receptor T-cell therapy.

Ariel Perez, MD, discusses polatuzumab vedotin in combination with bendamustine and rituximab since garnering approval from the FDA and studies that evaluated the combination.

A phase 1/2 trial investigating GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas will begin following the acceptance of an investigational new drug application for the agent.

In an interview with Targeted Oncology, Craig Sauter, MD, discusses available treatments for patients with central nervous system lymphoma and research that will provide more developments moving forward in this space.

During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the history of the use of brentuximab vedotin in Hodgkin lymphoma and how to evaluate patients after primary therapy.

Tirabrutinib has received orphan drug status from the FDA and is being studied in the phase 2 PROSPECT study for patients with primary central nervous system lymphoma.

A study of isatuximab and cemiplimab in 3 lymphoma subtypes will not continue, for reasons unrelated to safety.

Soligenix has requested a Type A meeting with the FDA to get clarity around the item needed to complete the new drug application of SGX301 for patients with early-stage cutaneous T-cell lymphoma.

In a vote of 11 to 2, the FDA's Oncologic Drugs Advisory Committee voted for the benefit/risk profile of polatuzumab vedotin in combination with R-CHP, based on findings from the confirmatory POLARIX trial.

In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.

The injectable formulation of nelarabine has been granted FDA approval to treatment 2 hematologic malignancies.

In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.

While JCAR021 showed durable responses, there was a high rate of neurotoxicity when given at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma.

Further guidance from the FDA will be requested for the new drug application submission for SGX301 for the treatment of early-stage cutaneous T-cell lymphoma.

A phase 3 trial of bortezomib, dexamethasone, rituximab, and cyclophosphamide shortened the median time to first response and increased the number of patients with Waldenström's macroglobulinemia.